Source comparison
CJC-1295 No DAC Ipamorelin Stack: Research Application Comparison
Comparison of Single vs Stacked Peptide Administration in GH Research Protocols The table below compares growth hormone release outcomes, receptor mechanisms, and research applications for single-peptide protocols versus the combined CJC-1295 no DAC and Ipamor
This comparison does not assign a generated winner or score.
- Comparison of Single vs Stacked Peptide Administration in GH Research Protocols
- The table below compares growth hormone release outcomes, receptor mechanisms, and research applications for single-peptide protocols versus the combined CJC-1295 no DAC and Ipamorelin stack.
- CJC-1295 no DAC alone
- 2.0–2.5× baseline
- GHRH receptor agonism; increases cAMP and calcium influx in somatotrophs
- 90–120 minutes (pulsatile)
- Studying acute GHRH pathway response; short-duration GH pulse modeling
- Useful for isolated GHRH studies but limited by endogenous somatostatin tone. Plateau effect common
- Ipamorelin alone
- 2.2–2.8× baseline
- GHS-R1a (ghrelin receptor) agonism; reduces somatostatin inhibition and stimulates GH vesicle release
- 2–3 hours
- Ghrelin pathway research; appetite signaling studies; selective GHS response without cortisol or prolactin elevation
- Cleaner selectivity than older GHS compounds (GHRP-6, GHRP-2) but ceiling-limited without concurrent GHRH signal
- CJC-1295 no DAC + Ipamorelin stack (1:1 ratio)
- 5.0–7.5× baseline
- Dual-pathway: GHRH receptor + ghrelin receptor co-activation; synergistic amplification through complementary signaling cascades
- 2–3 hours (sustained pulse)
- Gold-standard protocol for maximal pulsatile GH research; body composition studies; anabolic signaling pathway research
- Produces the highest amplitude GH pulses in research models; most published GH secretagogue studies use this combination for maximum signal-to-noise ratio
- Sermorelin alone (GHRH analog alternative)
- 1.8–2.3× baseline
- GHRH receptor agonism; shorter half-life (5–10 min) than CJC-1295 no DAC
- 30–60 minutes
- Rapid-pulse GH studies; ultra-short duration protocols
- Shorter half-life limits experimental flexibility; less stable than modified CJC-1295 no DAC
- Hexarelin alone (older GHS)
- 2.5–3.5× baseline
- GHS-R1a agonism; also elevates cortisol and prolactin (non-selective)
- 2–4 hours
- Broad GHS research; appetite and stress hormone interaction studies
- Potent but lacks selectivity. Cortisol elevation confounds GH-specific research outcomes